Join
Live feed
·
PRReleasevia Quantisnow
Cocrystal Pharma Inc. logo

Cocrystal Pharma Announces Last Subject Dosed in Phase 1b Human Challenge Study Evaluating CDI-988 for Norovirus Prevention and Treatment

ByQuantisnow·Wall Street's wire, on your screen.
COCP· Cocrystal Pharma Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track COCP (Cocrystal Pharma Inc.) and more on Quantisnow.